Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in diverse cancers, which contributes to the proliferation and survival of cancer cells by upregulating apoptosis inhibitors and cell cycle regulators. Suppressor of cytokine signaling 1 (SOCS1) is an important negative regulator of STAT pathways and is frequently silenced in many types of cancers. In this study, we used oncolytic adenoviral vector to deliver SOCS1 gene (AdCN305-SOCS1) to treat hepatocellular carcinoma (HCC). Our data showed that SOCS1 was downregulated in HCC cells by hypermethylation. AdCN305-SOCS1 was found selectively replicated, which led to SOCS1 overexpression in HCC cells. Infection of HCC cells with AdCN305-SOCS1 resulted in inhibition of STAT3 phosphorylation and downregulation of survivin, cyclin D1, Bcl-xL and C-myc. AdCN305-SOCS1 exhibited strong cytotoxicity to HCC cells by inducing apoptosis in vitro and in vivo. This study suggests that transfer of SOCS1 by an oncolytic adenovirus may be a potent antitumor approach for cancer therapy.
INTRODUCTION
Signal transducer and activator of transcription (STAT) signaling pathway can be activated by cytokines and growth factors. Janus kinases (JAKs) activate STAT by phosphorylation, which leads to STAT dimerization and nuclear translocation. This process results in transcription of target genes that are related to cell survival and proliferation.
1,2 STAT3 is the most important member of the STAT family, which is essential for signaling transduction and gene transcription initiated by a wide range of cytokines and growth factors. 1, 2 Considerable evidence suggests that activated STAT3 functions as an oncogenic protein in many kinds of cancers. STAT3 is constitutively activated in both hematological malignancies and solid tumors, including leukemia, lung cancer, head and neck cancer, prostate cancer, breast cancer, salivary gland cancer, pancreatic cancer and hepatocellular carcinoma (HCC). 3 --8 The constitutive activation of STAT3 in cancer cells results in overexpression of many genes that are involved in promoting cell proliferation and migration, decreasing cell apoptosis, inducing tumor angiogenesis and suppressing immune responses. 1 --8 Inhibition of the activated STAT3 pathway induces tumor cell apoptosis and suppresses tumor growth, suggesting that STAT3 could be a potential target for cancer therapy. 9 --13 Suppressor of cytokine signaling 1 (SOCS1) is described as a member of the SOCS family with eight proteins (SOCS1--7 and CIS). It plays an important role in a classical negative feedback loop to downregulate cytokine signal transduction. SOCS1 is an important negative regulator of JAK/STAT pathway. 14 Anomalous expression of SOCS-1 was found to be involved in some human diseases.
14 It has been revealed that SOCS1 is frequently silenced in several kinds of tumors for aberrant hypermethylation on the CpG islands in its functional promoter. 15 --19 The previous studies have shown that the levels of both SOCS1 and phosphorylated STAT3 were negatively correlated in the different types of cancers. 15, 20, 21 Thus, silence of SOCS1 in tumors may result in elevating the phosphorylated STAT3 level and promoting oncogenesis. It has been shown that SOCS1 peptide mimetic could inhibit constitutive activation of STAT3 in prostate cancer cells. 22 These findings suggest that the inhibition of STAT3 activity by overexpressed SOCS1 in tumor cells may suppress tumor growth. By this approach, an oncolytic adenoviral vector, which can preferentially replicate in tumor cells, is used to deliver SOCS1 gene. Our previous studies have shown that oncolytic adenoviral vectors carrying apoptosis-inducing genes possessed strong antitumor activity in vitro and in vivo. 23 --25 In this study, the oncolytic adenoviral vector can target tumor cells through human telomerase reverse transcriptase and retinoblastoma pathways because both pathways are actively involved in the carcinogenesis. 26 Our oncolytic adenoviral vector can selectively replicate in most tumor cells owing to the replacement of the native E1A promoter by human telomerase reverse transcriptase and deletion of the CR2 region.
27 SOCS1 expression was controlled by an endogenous adenoviral major late promoter, which restricted SOCS1 expression within the tumor microenvironment. 28, 29 In order to deliver SOCS1 to tumor cells that were not infected with oncolytic adenoviral vector armed with SOCS1, a cell-penetrating peptide (cpp), 12 amino acids from a hydrophobic signal sequence from fibroblast growth factor 4 with the capacity to deliver peptides, proteins and oligonucleotides into intact cells, was attached to the N terminal of SOCS1. 30, 31 Consequently, intracellular protein SOCS1 could have a bystander effect and achieve a better antitumor activity.
RESULTS

Loss of SOCS1 expression in HCC cells
To determine the status of SOCS1 and phosphorylated STAT3 in HCC cells, we analyzed the expression of endogenous SOCS1 in different HCC cell lines (Bel-7404, Hep3B, SMMC7721 and Huh-7) and normal liver cell line (L02) by western blotting. We found that SOCS1 transcript was absent and phosphorylated STAT3 was elevated in all tested HCC cell lines. In contrast, high levels of SOCS1 and low levels of phosphorylated STAT3 were observed in L02 normal cells (Figures 1a and b) . We also found that the expression of SOCS1 was restored by treatment of HCC cells with an inhibitor of methylation, 5-Aza-dC, indicating that SOCS1 might be silenced in HCC cells by hypermethylation (Figure 1c ). These data indicate that hypermethylation of SOCS1 results in the downregulation of SOCS1 and induces activation of STAT3.
Selective replication of oncolytic adenoviral vectors in HCC cells in vitro In order to deliver the SOCS1 gene into HCC cells with high efficiency, we engineered recombinant oncolytic adenoviral vectors carrying SOCS1, and HcRed reporter gene driven by adenovirus major late promoter (AdCN305-SOCS1 and AdCN305-HcRed). The structures of these vectors were shown in Figure 2a . To analyze whether exogenous SOCS1 could be expressed properly in the cells infected with oncolytic adenoviruses, the level of SOCS1 was detected in HCC cells (Bel-7404, Hep3B and Huh-7) infected with AdCN305-SOCS1 or AdCN305-HcRed. Figure 2b showed that the HCC cells infected with AdCN305-SOCS1 expressed a high level of SOCS1 protein while SOCS1 was undetectable in HCC cells infected with AdCN305-HcRed (Figure 2b ).
To examine whether expression of SOCS1 could interfere with the selective replication capability of oncolytic adenoviruses in HCC cell lines, a progeny assay was performed in the supernatants and the cell lysates of HCC cells (Bel-7404, Hep3B and Huh-7) and normal cells (L02) infected with AdCN305-SOCS1, AdCN305-HcRed or wild-type adenovirus (Ad-wt). As shown in Figure 2c , the yield of virus production was slightly lower in the lysates of HCC cells infected with AdCN305-SOCS1, as compared with the lysates of cells infected with AdCN305-HcRed and Ad-wt. Interestingly, the level of virus was significantly increased in the supernatants of HCC cells infected with AdCN305-SOCS1, as compared with the supernatants of cells infected with AdCN305-HcRed and Ad-wt. In contrast, the level of virus was obviously reduced in both supernatants and lysates of normal cells infected with AdCN305-SOCS1 and AdCN305-HcRed, as compared with Ad-wt. These data indicate that the expression of SOCS1 did not affect the selective replication capability of oncolytic vectors and result in increased virus release from infected cells. Furthermore, we also examined the expression of E1A, cleaved caspase 3 and poly (ADP-ribose) polymerase (PARP) in HCC and normal cells after infection with AdCN305-SOCS1. We found that the level of adenoviral E1A expression was much higher in HCC cells than in normal cells. High levels of expression of cleaved caspase 3 and PARP proteins were observed in HCC cells, as compared with that in normal cells (Figure 2d ). These results indicated that oncolytic adenoviral vectors armed with SOCS1 could selectively replicate and induce apoptosis in HCC cells, but not in normal cells.
Cytotoxicity induced by oncolytic adenoviral vectors in HCC cells in vitro
To analyze the antitumor efficiency of recombinant adenoviruses, HCC cell lines (Bel-7404, Hep3B, Huh-7 and SMMC7721) and a normal cell line (L02) were infected with AdCN305-SOCS1, AdCN305-HcRed or Ad-wt, and cell survival was determined by (3-(4, 5-dimethylthiazol-2-yl)-2, 5-dipenyltetrazolium bromide) assay. As shown in Figure 3a , both AdCN305-HcRed and Ad-wt could induce cytotoxicity to HCC cells at a similar level in a time-dependent manner. Moreover, AdCN305-SOCS1 could significantly reduce the viability of HCC cells, as compared with that induced by AdCN305-HcRed or Ad-wt. In contrast, oncolytic adenoviruses AdCN305-HcRed and AdCN305-SOCS1 did not induce cytotoxicity to normal cell line L02. Furthermore, we observed increased cytotoxicity to HCC cells in a dose-dependent manner, as compared with that induced by AdCN305-HcRed or Ad-wt ( Figure 3b ). These data indicate that AdCN305-SOCS1 can exert obvious cytotoxicity to HCC cells in vitro.
Inhibition of STAT3 phosphorylation and its downstream targets by oncolytic adenoviral vectors
To confirm whether exogenous expression of SOCS1 could negatively regulate STAT3 activation and decrease expression of downstream proteins of STAT3, HCC cells were infected with AdCN305-SOCS1 and levels of total STAT3, phosphorylated STAT3, Bcl-xL, cyclin D1, C-myc and survivin were measured by western blotting or reverse transcription-polymerase chain reaction (RT-PCR). As shown in Figure 4 , AdCN305-SOCS1 dramatically reduced the level of phosphorylated STAT3, with no effect on total STAT3 ( Figure 4 ). Furthermore, we found that expression of Bcl-xL, cyclin D1, C-myc and survivin was reduced after infection with AdCN305-SOCS1 ( Figure 4 ). These data indicated that SOCS1 was a potent negative regulator of STAT3 transduction pathway and subsequently reduces expression of the inhibitor of apoptosis and regulator of cell cycle.
Induction of apoptosis in HCC cells after infection with oncolytic adenoviral vectors in vitro
To examine whether SOCS1 could induce apoptosis in HCC cells, HCC cells were infected with AdCN305-SOCS1, AdCN305-HcRed or Ad-wt. Figure 5a showed that infection of HCC cells with AdCN305-SOCS1 led to remarkably morphological changes representing apoptosis, such as chromatin condensation, nuclear fragmentation and apoptotic body formation in HCC cells. Fluorescence-activated cell sorting analysis was performed to examine apoptosis induced by AdCN305-SOCS1. Our result showed that the apoptotic rate induced by AdCN305-SOCS1 was significantly higher than that induced by AdCN305-HcRed or Adwt (Figure 5b) . Furthermore, activation of the caspase pathway was examined to explore the mechanism of HCC cell apoptosis. As shown in Figure 5c , the cleavage of caspase 3 and PARP was obviously increased in HCC cells treated with AdCN305-SOCS1, as compared with AdCN305-HcRed or phosphate-buffered saline (PBS). These results suggested that AdCN305-SOCS1 could remarkably induce HCC cells' apoptosis by activation of caspase pathway.
Antitumor activity by oncolytic adenoviral vectors in an animal model with the established tumors To evaluate the antitumor activity of the recombinant adenoviruses under in vivo conditions, Bel-7404 human liver tumor xenograft model was established in nude mice. When the tumors grew to 180 --220 mm 3 , the animals were treated by intratumor injection of AdCN305-SOCS1, AdCN305-HcRed, Ad-wt or PBS as a control. As shown in Figure 6 , the tumors in the control animals receiving PBS grew progressively during the course of the experiment. On the contrary, the animals treated with control vector AdCN305-HcRed or Ad-wt exhibited a significant suppression of tumor growth. Treatment with AdCN305-SOCS1 resulted in remarkable inhibition of tumor growth, in comparison with animals treated with either AdCN305-HcRed or Ad-wt ( Figure 6 ). Histological analysis of tumors showed that treatment with AdCN305-SOCS1 caused profound cell death and necrosis in the tumor mass (Figure 7 ). Immunohistochemistry analysis showed that high level of adenovirus hexon proteins was detected in tumor after treatment with AdCN305-SOCS1 or Ad-wt, indicating that AdCN305-SOCS1 could replicate in HCC cells in in vivo condition (Figure 7 ). Immunohistochemistry analysis also showed high level of phosphorylated STAT3 in tumors treated with PBS or Ad-wt, whereas no phosphorylated STAT3 was detected in tumor after treatment with AdCN305-SOCS1 (Figure 7 ). These results Therapy of cancer by SOCS1 L Liu et al revealed that AdCN305-SOCS1 could selectively replicate in tumor and inhibit phosphorylation of STAT3 to achieve remarkable antitumor activity in vivo.
DISCUSSION
HCC is an aggressive malignancy with poor prognosis and is known to resist to chemotherapy and radiotherapy. HCC represents as one of the most difficult cancers to been treated. 32 Biological therapies, including gene therapy, have shown great promise for the treatment of HCC. 32, 33 Preclinical and clinical studies show that gene therapeutic strategies have achieved significantly antitumor activity. 23, 25, 34 However, present strategies are not effective enough to eliminate cancer completely, particularly in human patients. 35, 36 Therefore, it is needed to explore the potent vectors and therapeutic genes for this purpose.
Increasing evidence has shown that STAT3 is constitutively activated in various cancer cells. It has been suggested that persistently activated STAT3 acts as an oncogene and serves as a potent target for cancer therapy. Several approaches have been applied to modulate the STAT3 pathway and induce antitumor activity. Our previous work has confirmed that SOCS3, negative regulator of STAT3 activation, was silenced in HCC cells and transfer of SOCS3 had antitumor ability in vitro and in vivo. 37 In this study, we investigated whether SOCS1, another negative regulator of STAT3 activation, could be used as therapeutic gene for treatment of HCC.
To achieve the maximal transduction efficiency in cancer cells, it is needed to apply replication-competent viral vectors. It has shown that oncolytic adenoviruses could transduce tumor cells effectively and exhibit safety profile. 38, 39 Our previous studies have constructed double-regulated oncolytic adenoviral vector that could target human telomerase reverse transcriptase and retinoblastoma pathways. This vector only selectively replicates in tumor cells. 27 Therefore, we used this vector to deliver SOCS1 gene for the therapy of HCC. As SOCS1 is an intracellular protein, we modified SOCS1 by inserting cpp to its N terminal to enhance SOCS1 activity.
Our data showed that SOCS1 was downregulated in HCC cells. Downregulation of SOCS1 expression was due to hypermethylation, because inhibitor of methylation, 5-Aza-ds, could restore expression of SOCS1 in HCC cells, which is consistent with previous studies. 16 --18 Our results showed that there was a high level of E1A in tumor cells after infection with AdCN305-SOCS1. The AdCN305-SOCS1 specifically replicated in HCC cells. In addition, high level of SOCS1 could be expressed in HCC cells after being infected with AdCN305-SOCS1, indicating that AdCN305-SOCS1 could efficiently deliver SOCS1 into HCC cells.
Our data indicated that AdCN305-SOCS1 exhibited strong cytotoxicity in HCC cells and this cytotoxic effect is much higher than that induced by Ad-wt or AdCN305-HcRed. Most importantly, AdCN305-SOCS1 could not replicate in normal cells and it did not induce any cytotoxicity in normal cells. We also demonstrated that transfer of SOCS1 by AdCN305-SOCS1 could dramatically inhibit STAT3 phosphorylation and reduce the expression of downstream proteins of STAT3, including Bcl-xL, survivin, cyclin D1 and C-myc. The Bcl-xL and survivin are antiapoptosis proteins, and cyclin D1 and C-myc are important regulation factors in cell cycle. These results indicated that strong cytotoxic effect of AdCN305-SOCS1 on HCC cells might be induced by alternation of cell cycle and induction of cells' apoptosis. Our data further demonstrated that AdCN305-SOCS1 could induce cell apoptosis by induction of cleavage of caspase 3 and PARP, the main and important mechanisms for induction of cell apoptosis. The study indicated that AdCN305-SOCS1 could induce HCC cell apoptosis through the activation of caspase pathway by downregulating Bcl-xL and survivin proteins. Our data suggested that the inhibition of STAT3 activity could decrease HCC cell proliferation and increase HCC cell sensitivity to apoptosis by restoring SOCS1 in HCC cells.
To evaluate the antitumor ability of AdCN305-SOCS1 in vivo, we treated the established tumors in an animal model. The virus could successfully replicate in tumors and exhibit the strong ability to inhibit tumor growth. The treatment with AdCN305-SOCS1 resulted in significant tumor regression, in comparison with that with AdCN305-HcRed or Ad-wt. Inhibition of STAT3 phosphorylation was also observed in the tumor treated with AdCN305-SOCS1, indicating that transfer of SOCS1 could suppress tumor growth by the inhibition of STAT3 activity and downregulating downstream protein of STAT3 in vivo.
In summary, AdCN305-SOCS1, a double-regulated oncolytic adenovirus harboring SOCS1, was successfully generated. 
MATERIALS AND METHODS
Cell cultures
Bel-7404, Hep3B, Huh-7, SMMC7721 (human HCC cell lines) and L02 (normal human liver cell line) were purchased from Shanghai Cell Collection (Shanghai, China). HEK293 (human embryonic kidney cells) was obtained from Microbix Biosystems Inc. (Toronto, ON, Canada). Bel-7404, Hep3B, SMMC7721, Huh-7, L02 and HEK293 were cultured in Dulbecco's modified Eagle's medium (GIBCO-BRL, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (GIBCO-BRL) at 37 1C under a 5% CO 2 condition.
Construction of oncolytic adenoviral vectors
Human SOCS1 gene was obtained from the plasmid of p-SOCS1. The cpp-SOCS1 was obtained by PCR amplification with the primers that contained the sequence of cpp from fibroblast growth factor 4. The cppSOCS1 gene was excised by NcoI/BamHI from pMD-18T plasmids and cloned into a pBS/internal ribosome entry site (IRES) plasmid to get pBS/ IRES-SOCS1. The IRES-SOCS1 was released from pBS/IRES-SOCS1 with SalI and then cloned into pCZ305 at the same site to obtain pCZ305-SOCS1. The recombinant oncolytic adenovirus plasmid pCN305-SOCS1 was generated by homologues recombination in Escherichia coli by using a SnaBI fragment from pCZ305-SOCS1 and pCN103, which contains an oncolytic adenovirus backbone. All plasmid constructs were confirmed by digestion with restrictive enzymes, PCR and DNA sequencing.
Generation, purification and titration of recombinant adenoviruses
To get the viruses, the plasmid pCN305-SOCS1 was digested by PacI and transfected into HEK293 cells by Effectene (Qiagen, Hilden, Germany). The recombinant adenoviruses were amplified in HEK293 cells and purified by 
Cell viability assay
Cells were seeded in 96-well plates at a density of 1 Â 10 4 per well. When cells grew to subconfluence, they were infected with AdCN305-SOCS1, AdCN305-HcRed or Ad-wt at a multiplicity of infection (MOI) of 10. Fresh medium containing 0.5 mg ml À1 (3-(4, 5-dimethylthiazol-2-yl)-2, 5-dipenyltetrazolium bromide) (Sigma Chemical Co., St Louis, MO, USA) solution was added to each well at different time after infection. Cells were incubated at 37 1C for 4 h, and then 150 ml of dimethyl sulfoxide was added to each well and mixed thoroughly for 10 min. Absorbance was read at 595 nm with a DNA expert (Tecan, Männedorf, Switzerland). For a dose-dependent assay, the cells were infected with different MOI, and cell survival was determined at 96 h after infection.
Virus progeny assay
To determine virus progeny, HCC or normal cells were infected with Ad-wt, AdCN305-HcRed or AdCN305-SOCS1 at a MOI of 5. After 48 h, the supernatants and cells were collected separately. The cells were resuspended in PBS, and the virus was released by freeze and thaw for three cycles. Virus production in supernatants and cell lysates were determined by tissue culture infectious dose 50 assay on HEK293 cells.
Western blotting
Total protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 8 --12% gels and transferred to 0.45 mm nitrocellulose (Millipore, Billerica, MA, USA). The membranes were blocked for 3 h with 5% bovine serum albumin overnight at 4 1C before incubation with primary antibodies. The primary antibodies included anti-STAT3, anti-SOCS1, anti-C-myc and anti-PARP from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-phospho-STAT3 (Tyr705), anti-cyclin D1, anti-Bcl-xL and anti-b-actin from Cell Signaling Technology (Beverly, MA, USA), anticaspase 3 from Epitomics (Burlingame, CA, USA) and anti-E1A from Abcam (Cambridge, UK). The membranes were then incubated with anti-rabbit infrared dye 700 and anti-mouse infrared dye 800 (Li-Cor, Lincoln, NE, USA). The fluorescent signal was revealed through the Odyssey infrared imaging system (Li-Cor). 
Immunohistochemistry
For immunohistochemical analysis, the tumors treated with viruses for 6 days were harvested and fixed in 4% paraformaldehyde, embedded in paraffin and cut into 4-mm sections. These sections were stained with hematoxylin --eosin or incubated with terminal deoxynucleotidyl transferase dUTP nick-end labeling, hexon and phospho-STAT3 (Tyr705) antibodies. The antibody staining signals were amplified by a biotinylated peroxidase-conjugated streptavidin system (Bio-Genex Laboratories, San Reman, CA, USA).
Statistical analysis
Each experiment was performed at least three times. The statistical significance was calculated by analysis of variance when more than two groups were compared or by Student's t-test when only two groups were compared. Differences were considered statistically significant at Po0.05.
